scholarly journals Restoring Fertility in Sterile Childhood Cancer Survivors by Autotransplanting Spermatogonial Stem Cells: Are We There Yet?

2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Robert B. Struijk ◽  
Callista L. Mulder ◽  
Fulco van der Veen ◽  
Ans M. M. van Pelt ◽  
Sjoerd Repping
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Childhood Cancer ◽  
Cell Transplantation ◽  
Childhood Cancer Survivors ◽  
Spermatogonial Stem Cells ◽  
Spermatogonial Stem Cell

Current cancer treatment regimens do not only target tumor cells, but can also have devastating effects on the spermatogonial stem cell pool, resulting in a lack of functional gametes and hence sterility. In adult men, fertility can be preserved prior to cancer treatment by cryopreservation of ejaculated or surgically retrieved spermatozoa, but this is not an option for prepubertal boys since spermatogenesis does not commence until puberty. Cryopreservation of a testicular biopsy taken before initiation of cancer treatment, followed byin vitropropagation of spermatogonial stem cells and subsequent autotransplantation of these stem cells after cancer treatment, has been suggested as a way to preserve and restore fertility in childhood cancer survivors. This strategy, known as spermatogonial stem cell transplantation, has been successful in mice and other model systems, but has not yet been applied in humans. Although recent progress has brought clinical application of spermatogonial stem cell autotransplantation in closer range, there are still a number of important issues to address. In this paper, we describe the state of the art of spermatogonial stem cell transplantation and outline the hurdles that need to be overcome before clinical implementation.

Late effects and quality of life of childhood cancer survivors: Part 1. Impact of stem cell transplantation

2010 ◽  
Vol 91 (5) ◽  
pp. 865-876 ◽  
Author(s):  
Yasushi Ishida ◽  
Misato Honda ◽  
Shuichi Ozono ◽  
Jun Okamura ◽  
Keiko Asami ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Cell Transplantation ◽  
Late Effects ◽  
Childhood Cancer Survivors

scholarly journals Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation—a cohort study

2020 ◽  
Author(s):  
Maria Otth ◽  
◽  
Christina Schindera ◽  
Tayfun Güngör ◽  
Marc Ansari ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Childhood Cancer Survivors ◽  
Hematopoietic Stem ◽  
Increased Risk

AbstractChildhood cancer survivors treated with hematopoietic stem cell transplantation are at high risk for pulmonary morbidity and mortality. In this retrospective study we described transplant characteristics of pediatric patients who underwent hematopoietic stem cell transplantation in Switzerland and how these characteristics changed over time, compared self-reported pulmonary outcomes between transplanted and non-transplanted survivors, and investigated risk factors for the reported pulmonary outcomes. As part of the population-based Swiss Childhood Cancer Survivor Study, we sent questionnaires to all ≥5-year childhood cancer survivors diagnosed 1976–2010 at age ≤20 years. We included 132 transplanted survivors and 368 matched non-transplanted survivors. During the study period transplant characteristics changed, with decreasing use of total body irradiation and increased use of peripheral blood stem cells and mismatched and unrelated donors as transplant source. One-fifth of transplanted survivors (20%, 95%CI 13–27%) and 18% of non-transplanted survivors (95%CI 13–21%) reported at least one pulmonary outcome. None of the analyzed factors was significantly associated with an increased risk of pulmonary outcomes in multivariable analysis. We found that pulmonary outcomes were frequently reported in transplanted and non-transplanted childhood cancer survivors, indicating a strong need for long-term pulmonary follow-up care.

scholarly journals Co-transplantation of mesenchymal stem cells improves spermatogonial stem cell transplantation efficiency in mice

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Prashant Kadam ◽  
Elissavet Ntemou ◽  
Yoni Baert ◽  
Sven Van Laere ◽  
Dorien Van Saen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Spermatogonial Stem Cell

scholarly journals Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report

2019 ◽  
Vol 3 (11) ◽  
pp. 2179-2183
Author(s):  
Ayako Nagayama ◽  
Kenji Ashida ◽  
Kanoko Moritaka ◽  
Mami Hidaka ◽  
Mizuki Gobaru ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Stem Cell ◽  
Insulin Sensitivity ◽  
Stem Cell Transplantation ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Total Body Irradiation ◽  
Childhood Cancer Survivors ◽  
Total Body

Abstract Most childhood cancer survivors who undergo hematopoietic stem cell transplantation subsequently develop impaired glucose tolerance and hypertriglyceridemia. These conditions are presumably associated with total-body irradiation–related acquired lipodystrophy and may lead to cardiovascular disease. Metreleptin (recombinant leptin) may help improve the lipoprotein profile, insulin sensitivity, and quality of life of patients with total-body irradiation-related lipodystrophy. This report describes the safe and effective use of metreleptin supplementation for insulin resistance and dyslipidemia in acquired incomplete lipodystrophy. A 24-year-old Japanese woman with diabetes mellitus and hypertriglyceridemia was admitted to our hospital. She was diagnosed with acute lymphocytic leukemia at 3 years of age and had undergone systemic chemotherapy and total-body irradiation before allogeneic stem cell transplantation. She was also diagnosed with hypertriglyceridemia and diabetes mellitus at 11 years of age. She had a low adiponectin level, low-normal leptin level, and diabetes mellitus with marked insulin resistance. Thus, acquired incomplete lipodystrophy was diagnosed. Her serum triglyceride and lipoprotein profiles improved within 1 month of treatment initiation. Glycemic metabolism and insulin sensitivity in the skeletal muscles improved after 6 months. As previously reported, metreleptin therapy is effective in improving lipid and glycemic profiles in generalized lipodystrophy. In the present case, we considered that metreleptin supplementation could reduce the remnant VLDL cholesterol fraction and improve diabetes mellitus. We conclude that it may be an effective alternative therapy for improving the expected prognosis of patients with acquired incomplete lipodystrophy, including childhood cancer survivors.

Sign in / Sign up

Export Citation Format

Share Document